In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please cancel claim 21 without prejudice to its presentation in another application as follows:

1-11. (cancelled).

12. (previously presented) A compound selected from:

2-methyl-N.1.5-triphenyl-1H-pyrrole-3-carboxamide:

1-(4-chlorophenyl)-2-methyl-N.5-diphenyl-1*H*-pyrrole-3-carboxamide;

1-(4-methoxyphenyl)-2-methyl-N,5-diphenyl-1H-pyrrole-3-carboxamide;

5-(2,4-dichlorophenyl)-2-methyl-N,1-diphenyl-1H-pyrrole-3-carboxamide;

1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-*N*-phenyl-1*H*-pyrrole-3-carboxamide:

5-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-*N*-phenyl-1*H*-pyrrole-3-carboxamide:

5-(2,4-dimethoxyphenyl)-2-methyl-N,1-diphenyl-1H-pyrrole-3-carboxamide;

1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-*N*-phenyl-1*H*-pyrrole-3-carboxamide:

5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-*N*-phenyl-1*H*-pyrrole-3-carboxamide:

2-methyl-1,5-diphenyl-N-piperidin-1-yl-1H-pyrrole-3-carboxamide;

1-(4-chlorophenyl)-2-methyl-5-phenyl-N-piperidin-1-yl-1H-pyrrole-3-carboxamide;

1-(4-methoxyphenyl)-2-methyl-5-phenyl-N-piperidin-1-yl-1H-pyrrole-3-carboxamide;

5-(2.4-dichlorophenyl)-2-methyl-1-phenyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide:

carboxamide;

5-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide:

1-{[5-(2,4-dimethoxyphenyl)-2-methyl-1-phenyl-1*H*-pyrrol-3-yl]carbonyl}piperidine;

1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide:

5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide:

1-[(2-methyl-1,5-diphenyl-1*H*-pyrrol-3-yl)carbonyl]piperidine;

1-{[1-(4-methoxyphenyl)-2-methyl-5-phenyl-1*H*-pyrrol-3-yl]carbonyl}piperidine;

1-{[5-(2,4-dichlorophenyl)-2-methyl-1-phenyl-1*H*-pyrrol-3-yl]carbonyl}piperidine;

1-{[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-1*H*-pyrrol-3-

yl]carbonyl}piperidine;

 $1\hbox{-}\{[5\hbox{-}(2,4\hbox{-}dichlorophenyl)\hbox{-}1\hbox{-}(4\hbox{-}methoxyphenyl)\hbox{-}2\hbox{-}methyl\hbox{-}1$$H-pyrrol-3-1-(4,4)$$II-(4,4)$

yl]carbonyl}piperidine;

 $1-\{[1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-1 H-pyrrol-3-methyl-2-methyl-1 H-pyrrol-3-methyl-2-methyl-2-methyl-2-methyl-2-methyl-2-methyl-3-me$

yl]carbonyl}piperidine; and

1-{[5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrol-3-yl]carbonyl}piperidine;

and where applicable, tautomers, stereoisomers and racemates thereof as well as pharmaceutically acceptable salts and solvates thereof.

- 13. (cancelled).
- 14. (previously presented) A pharmaceutical composition comprising a compound of claim 12 and a pharmaceutically acceptable adjuvant, diluent or carrier.
- 15-19. (cancelled).
- 20. (previously presented) A compound selected from:

Ethyl 1-(4-chlorophenyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxylate,

Ethyl 1-(4-methoxyphenyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxylate,

Ethyl 5-(2,4-dichlorophenyl)-2-methyl-1-phenyl-1*H*-pyrrole-3-carboxylate,

- Ethyl 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-1H-pyrrole-3-carboxylate,
- Ethyl 5-(2,4-dichlorophenyl)- 1-(4-methoxyphenyl)-2-methyl-1H-pyrrole-3-carboxylate,
- Ethyl 5-(2,4-dimethoxyphenyl)-2-methyl-1-phenyl-1H-pyrrole-3-carboxylate,
- $\label{prop:local_equation} \mbox{Ethyl 1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-1$$H$-pyrrole-3-carboxylate,}$
- $Ethyl\ 5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-1 \ H-pyrrole-3-carboxylate,$
 - 1-(4-Chlorophenyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxylic acid.
 - 5-(2,4-Dichlorophenyl)-2-methyl-1-phenyl-1H-pyrrole-3-carboxylic acid,
 - 1-(4-Chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-1*H*-pyrrole-3-carboxylic acid,
 - 5-(2.4-Dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylic acid.
 - 5-(2.4-Dimethoxyphenyl)-2-methyl-1-phenyl-1*H*-pyrrole-3-carboxylic acid.
- 1-(4-Chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylic acid, and
 - 5-(2,4-Dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylic acid.
- 21-26. (cancelled).
- 27. (previously presented) A method of treating obesity in a mammal comprising administering a pharmacologically effective amount of a compound of claim 12 or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, to the mammal in need thereof